The Expert Angle
Medlior is a well-known and trusted industry leader.
Our team is dedicated to delivering high-quality research that provides a solid basis for informed decision-making.
Medlior’s Expert Angle offers the inside track on new studies, industry hot topics, and what you need to know in the fast-paced world of clinical research, all from the point of view of the Medlior team of experts. From the latest topics and trends to the foundations of health and medical research, Medlior explores topics relevant to clients and the world.
DLBCL Environmental Scan
Understanding and identifying the unmet need of aggressive B-cell lymphomas is critical for positioning new therapies
Aggressive B-cell lymphomas are a subset of non-Hodgkin’s lymphoma (NHL) that encompass a number of neoplasms that include both precursor lymphoid neoplasms and mature B-cell neoplasms, such as diffuse large B-cell lymphoma (DLBCL), primary...
Case Study: Multiple Myeloma
Medlior Health Outcomes Research was engaged by Celgene Canada (now a subsidiary of Bristol-Myers Squibb Company) to examine the treatment landscape for patients with multiple myeloma (MM) and the effects of lenalidomide (REVLMID®) as an immunomodulatory imide drug for both newly-diagnosed MM patients and relapsed/refractory MM patients.
...
Lipid-lowering Therapy Patterns and Low-density Lipoprotein-Cholesterol Management Among Patients with Acute Myocardial Infarction in Alberta, Canada
Medlior’s presentation focuses on a real-world evidence study sponsored by Amgen Inc. examining the management of patients with an acute myocardial infarction (AMI) in Alberta, Canada. AMI is a leader in disease burden and death worldwide. In order to combat AMI, modifiable factors that lower cholesterol, specifically low-density lipoprotein-cholesterol (LDL-C)...
Canadian real-world evidence on epidemiology, outcomes and economics of moderate-to-severe osteoarthritis
A systematic literature review
Osteoarthritis (OA) is a chronic joint disease that leads to a loss of articular cartilage, resulting in painful bone-on-bone contact. Females have a higher risk of developing OA compared to males, and obese individuals are three times more likely to develop OA. Currently, the population...
Coronavirus background and key questions
As the COVID-19 virus spreads, world governments implement control strategies
This article is about an emerging and rapidly evolving public health crisis. Case and death counts change daily. If you’re interested in learning the very latest information please consult the World Health Organization or your local governing body.
As...
Medlior partners with Calgary Universities for proof-of-concept study
Study on natural language processing and machine learning to develop oncology decision aid for multiple myeloma in Alberta
In Canada, approximately 2,900 people were diagnosed with multiple myeloma in 2017. Unique, targeted therapies are currently in development for multiple myeloma and will likely alter the disease course and survival rates.
...
Industry Predictions for 2020
Medlior is looking forward to a year of innovation in health outcomes research with Real World Evidence leading the way. See our predictions for 2020.
...
Looking Back on 2019
2019 has proven to be a great year for Medlior, the healthcare industry and Real World Evidence. Read our wrap on the last year here.
...
Using Integrated Real-World Data in Alberta to Develop Personalized Follow-up Care Pathways for Cancer Survivors
This study will provide an integrated data source to inform follow-up clinical care pathways for cancer survivors in Alberta
The odds of long-term recovery from cancer have never been better. In the 1940s only 25% of Canadians survived a cancer diagnosis, compared with 60% today.1 Simultaneously, cancer incidence continues to...
Real World Data and Inflammatory Bowel Disease
Real World Data could be used to create a better understanding of the burden of diseases such as inflammatory bowel disease and improve health outcomes
...
